GENELUX Corp annual report, FY2023

GENELUX Corporation — FY2023 Form 10-K

Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; it does not provide standalone fourth-quarter results. Genelux is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies. Its lead and only clinical-stage product candidate is Olvi-Vec; no product is approved for sale.

Financial results and position

Metric	FY2023	FY2022
Revenue	$0.17 million	$11.07 million
Research and development expense	$12.77 million	$9.08 million
General and administrative expense	$11.57 million	$5.00 million
Operating loss	$24.17 million	$3.01 million
Net loss	$28.30 million	$5.21 million
Basic and diluted loss per share	$1.16	$0.57
Cash used in operating activities	$20.28 million	$3.57 million

Revenue was not from commercial product sales. The prior-year amount primarily reflected license-related revenue, including the Newsoara agreement; FY2023 revenue was mainly for product supplied to Newsoara. As a development-stage company, product margins are not meaningful from the information presented.

At year-end, cash and cash equivalents were $9.42 million and short-term investments were $13.77 million, totaling $23.19 million. Current assets were $24.20 million and current liabilities were $6.55 million. Total liabilities were $8.42 million, including $2.52 million of lease liabilities; shareholder and convertible note balances were zero after repayment or conversion. Shareholders’ equity was $19.47 million, compared with a deficit of $35.78 million in 2022.

Financing activities provided $44.02 million in 2023, including IPO and private-placement proceeds, option and warrant exercises, and notes payable. The company also used $14.72 million in investing activities, largely to purchase short-term investments and property and equipment. The auditor’s report includes a going-concern explanatory paragraph, citing recurring losses and operating cash use and stating that substantial doubt exists about the company’s ability to continue as a going concern.

Material changes versus FY2022

Revenue fell by $10.90 million as FY2022 included substantial license revenue; operating expenses rose by $10.25 million.
Net loss increased by $23.09 million, while operating cash use increased by $16.70 million.
General and administrative costs rose with higher stock compensation, professional services and public-company costs; R&D costs increased largely with staffing and stock compensation.
The company completed its IPO and private placements and converted preferred stock and convertible debt into common stock. Common shares outstanding increased from 9.13 million at year-end 2022 to 26.79 million at year-end 2023.

Outlook, programs and key risks

Funding: Management said available cash and investments were expected to fund planned operating expenses and capital needs for at least 12 months from the filing. This estimate depends on assumptions and does not remove the disclosed going-concern uncertainty. Of $30 million in contracted remaining private-placement commitments, $6 million had been received; a $22 million investor had not paid and indicated an intention not to comply. The deadline for another $2 million was extended to March 31, 2024. Genelux was evaluating remedies.
PRROC Phase 3: The randomized registration trial targets approximately 186 patients, with topline results expected in the second half of 2025. The filing says the protocol was amended and enrollment was expected to begin upon IRB approvals, notwithstanding the earlier statement that enrollment began in Q3 2022. A national shortage of platinum chemotherapy had slowed some site enrollment; the company established a supply depot but could not guarantee timely resupply.
Earlier PRROC data: In a Phase 1b/2 study, the company reported an ORR of 54% among 24 evaluable patients, median PFS of 11.0 months and median overall survival of 15.7 months for Olvi-Vec-primed immunochemotherapy. These results came from an earlier study and comparisons cited by the company were against historical outcomes; the confirmatory Phase 3 trial remains a major uncertainty.
Other programs: U.S. Phase 2 NSCLC trial enrollment was expected to begin in the first half of 2024. Newsoara is generally obligated to fund the trial, but could defer reimbursement of certain U.S. startup costs until its next financing round. A China SCLC Phase 1b/2 trial is ongoing, with interim Phase 1 results expected in the second half of 2024. V2ACT’s pancreatic-cancer trial had not been scheduled to start.
Manufacturing and collaboration: Genelux is expanding its San Diego facilities and using a newer mammalian-cell manufacturing process. Regulatory comparability, production capacity, quality compliance and supplier availability could affect trial timing and results. Newsoara’s China license includes potential milestones of up to $160.5 million and sales royalties; these future payments depend on development and commercial milestones.
Unusual items: FY2023 other expenses included $3.15 million of financing costs and $0.40 million of debt-extinguishment costs. Stock-option repricing contributed $2.69 million of noncash expense. These items increased reported losses.
Principal risks: The company has no approved products or commercial sales, expects continuing losses and needs additional capital. Other material risks include clinical and regulatory failure or delay, patient enrollment, manufacturing changes, dependence on Newsoara and third parties, competition, reimbursement uncertainty, intellectual-property protection, cybersecurity and potential dilution. The company reported its previously pending litigation was dismissed with prejudice and the appeal was dismissed in February 2024.

Important facts for investors to verify

Current cash, investment balances, cash burn and whether the disclosed runway assumptions remain valid, especially given the unpaid private-placement commitments and going-concern paragraph.
Actual status of PRROC Phase 3 enrollment after protocol amendments and IRB approvals, and any changes to the expected second-half 2025 topline timing.
Whether the Phase 3 results support the efficacy and safety suggested by the earlier, small Phase 1b/2 study; assess the study design and comparator results rather than relying on historical comparisons.
Newsoara’s ability to fund the NSCLC trial and reimburse startup costs, and progress and funding for its China trials.
Manufacturing comparability and cGMP readiness for the newer process, and availability of platinum chemotherapy and other trial supplies.
Potential dilution from future fundraising, outstanding options and warrants, and the effect of any additional shares issued.